NCT03810924 is a NA clinical trial of Trier Social Stress Test in Alcohol Use Disorder, sponsored by Central Institute of Mental Health, Mannheim.

Who is sponsoring NCT03810924?

NCT03810924 is sponsored by Central Institute of Mental Health, Mannheim.

What drugs are being tested in NCT03810924?

Interventions in NCT03810924: Trier Social Stress Test, Ergometer, Barlab-Exposure, Reading Newspaper.

What condition does NCT03810924 study?

NCT03810924 studies Alcohol Use Disorder, Stress Reaction, Social Stress, Craving, Relapse, Addiction, Risk Behavior.

Is NCT03810924 still recruiting?

NCT03810924 is currently completed. Last updated 15 September 2023.

Last reviewed 2023-09-15 · How we verify

NCT03810924

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Stress-related Predictor Profiles in Human Addiction

Completed NA Last updated 15 September 2023

What this trial tests

NA trial testing Trier Social Stress Test in Alcohol Use Disorder in 121 participants. Completed in 8 July 2023.

Timeline

1 July 2019

Primary endpoint
30 September 2022

8 July 2023

Quick facts

Lead sponsor	Central Institute of Mental Health, Mannheim
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	121
Start date	1 July 2019
Primary completion	30 September 2022
Estimated completion	8 July 2023
Sites	1 location across Germany

Drugs / interventions tested

Trier Social Stress Test
Ergometer
Barlab-Exposure
Reading Newspaper

Conditions studied

Alcohol Use Disorder — all drugs for Alcohol Use Disorder →
Stress Reaction — all drugs for Stress Reaction →
Social Stress — all drugs for Social Stress →
Craving — all drugs for Craving →

Sponsor

Central Institute of Mental Health, Mannheim

Who can join

Adults 18 to 65, any sex, with Alcohol Use Disorder or Stress Reaction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Long-term aim is the definition of a setup of mobile sensors and their integration in a mobile infrastructure that allows the prediction of stress related alcohol intake in an ambulatory setting. Here, we aim to identify stress- and alcohol cue-related physiological markers in a lab experiment to assess interactions between acute psychological vs. physical stress exposure and alcohol cue-exposure regarding their effects on measures relevant for the development and maintenance of Alcohol Use Disorder (AUD). Further, we aim to identify neural correlates in brain circuits of motivational, cognitive, and affective processing. In addition to applying established stress-related markers, we will integrate innovative sensor-based measures.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Individual stress reactivity predicts alcohol craving and alcohol consumption in alcohol use disorder in experimental and real-life settings.
Zaiser J, Hoffmann S, Zimmermann S, Gessner T, et al · · 2025 · cited 1× · PMID 40610438 · DOI 10.1038/s41398-025-03447-8

Verify or expand the search:

Other trials of Trier Social Stress Test

Trials testing the same drug.

NCT04100213 — Real-Time Assessment of Stress and Stress Response · NA · withdrawn
NCT06977178 — Adverse Adolescent Pathways to Substance Use · NA · recruiting
NCT06105853 — Neurobehavioral Profiles of Adaptive Stress Responses in Individuals With Alcohol Use Disorder · NA · recruiting
NCT05795634 — Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease · NA · recruiting
NCT05570721 — Depression, Aging, Stress and Heart Health Study · NA · recruiting

Other recruiting trials for Alcohol Use Disorder

Currently open trials in the same condition.

NCT06860607 — Environment and Alcohol: A Pilot Study · Phase 1 · recruiting
NCT07325266 — Human Laboratory Study of Apremilast for Alcohol Use Disorder · Phase 2 · recruiting
NCT07046819 — Tirzepatide in MetALD · Phase 2 · recruiting
NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting
NCT07056894 — Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis · NA · recruiting

Other Central Institute of Mental Health, Mannheim trials

Trials by the same sponsor.

NCT06845124 — A Trial to Investigate the Effects of Cannabidiol Plus Naltrexone on Alcohol Craving in Patients With Alcohol Dependence · Phase 2 · recruiting
NCT00916201 — Evaluation Study of New Compounds With Potential Use in Schizophrenia · Phase 1 · withdrawn
NCT06959342 — Modification of Inhibitory Control and Craving Through Transcranial Direct Current Stimulation (tDCS) as an Add-On Treat · NA · recruiting
NCT06881810 — Enhancing Social Skills in Schizophrenia Spectrum Disorders - Oxytocin as add-on to Psychosocial Treatment · Phase 2 · recruiting
NCT05726045 — Increasing Smoking Cessation Success Through Sleep-amplified Memory Consolidation · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03810924 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Central Institute of Mental Health, Mannheim
Last refreshed: 15 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03810924.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing